findmyKOL
Clinical trialNCT03409276CompletedPhase 1Interventional

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment60HIV Infections
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of env (A,B,C,A/E)/gag (C) DNA and gp120 (A,B,C,A/E) protein/GLA-SE HIV-1 vaccines (PDPHV-201401) as a prime-boost regimen or co-administered in repeated doses, in healthy, HIV-1-uninfected adults.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Alabama Crs

    Birmingham, Alabama, United States

  • the Hope Clinic of the Emory Vaccine Center Crs

    Decatur, Georgia, United States

  • Fenway Health (fh) Crs

    Boston, Massachusetts, United States

  • University of Rochester Vaccines To Prevent Hiv Infection Crs

    Rochester, New York, United States

  • Case Clinical Research Site

    Cleveland, Ohio, United States

  • Penn Prevention Crs

    Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

GLA-SE adjuvantPlaceboEnv/gag DNA VaccineGp120 Protein Vaccine
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
16 Mar 2018
Primary completion
11 May 2020
Completion
22 Oct 2020
Last update posted
25 Apr 2022
Registered enrollment
60
Registry id
NCT03409276
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.